WE PERCEIVE. WE PREPARE. WE PROTECT.

Now Available: Listen to Season 2 of Countermeasures

Season 2 of Countermeasures takes a closer look at some of the places hit hardest by the opioid crisis. From elder care facilities to high schools, workplaces to correctional facilities, hear from advocates, public health experts, and people who are using their lived experience to make things better for their communities and discover a new way forward. 

LEARN MORE

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading The New Way Forward for public health.

Learn more

Capabilities

We are a leader in providing solutions that address public health threats and bring lifesaving, life-extending products to market.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    Emergent specializes in developing, manufacturing, and stockpiling medical countermeasures for military and civilian populations that target some of the deadliest public health threats.

  • Bioservices

    Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations.

Woman in Lab

At Emergent, our mission is to protect and enhance life.

View our 2023 Annual Report

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa’ (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial.
Read More

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2024.
Read More

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent’s strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical and biostatistics, and patient safety.
Read More
READ ALL NEWS

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.